SLNO Soleno Therapeutics Inc

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:

Event:	Jefferies Global Healthcare Conference
Day:	Wednesday, June 5, 2024
Time:	11:30 AM Eastern Time
Event:	Goldman Sachs 45th Annual Global Healthcare Conference
Day:	Tuesday, June 11, 2024
Time:	4:00 PM ET

A live audio webcast and replay of the events will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life.

Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578